Type I invariant NKT (iNKT) cells play a critical role in propagating injury, inflammation and fibrosis in inflammatory and fibrotic indications; GRI Bio's programs are built around inhibiting or activating specific NKT cell subsets to influence these disease processes. The company operates as a clinical-stage biotech with a proprietary NKT platform and multiple programs in development targeting high-unmet-need indications.
Cyborg Score Rationale
GRI underperformed the US Biotechs industry which returned 20.9% over the past year and underperformed the US Market which returned 16.6% over the past year. While the company has regained NASDAQ compliance and has a scientifically differentiated platform, it faces significant dilution pressure and remains pre-revenue with execution risks in clinical development.
Top Insights
Lead program GRI-0621 is in Phase 2 development for Idiopathic Pulmonary Fibrosis (IPF), a disease with only two approved treatments and significant clinical need
GRI-0803, a Type 2 NKT agonist targeting Systemic Lupus Erythematosus (SLE), progressed to clinical development with Phase 1a/1b initiation planned
Regained NASDAQ Minimum Bid Price compliance in March 2025 after previous delisting pressure, indicating operational stabilization
Raised $5.5 million in public offering in February 2024, extending runway but highlighting ongoing capital needs and shareholder dilution concerns
Named Competitors
Regeneron Immunology Portfolio — Inflammatory and autoimmune disease treatments
Gilead Immunology — Inflammatory disease treatments and immunotherapies
Palisade Bio (PALI) — Early-stage immunology biotech
Aptevo Therapeutics (APVO) — Cell therapy and immunotherapy development